Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

Thomas, K.S.; Apfelbacher, C.A.; Chalmers, J.R.; Simpson, E.; Spuls, P.I.; Gerbens, L.A.A.; Williams, HC; Schmitt, J.; Gabes, M.; Howells, L.; Stuart, B.L.; Grinich, E.; Pawlitschek, T.; Burton, T.; Howie, L.; Gadkari, A.; Eckert, L.; Ebata, T.; Boers, M.; Saeki, H.; Nakahara, T.; Katoh, N.

doi:10.1111/bjd.19751

All Outputs (6)

Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study (2021)
Journal Article
Persson, M. S., Harman, K. E., Thomas, K. S., Chalmers, J. R., Vinogradova, Y., Langan, S. M., …Gran, S. (2021). Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. British Journal of General Practice, 71(713), e904-e911. https://doi.org/10.3399/BJGP.2020.0870

Background: Oral prednisolone is the mainstay treatment for bullous pemphigoid, an autoimmune blistering skin disorder affecting older people. Treatment with moderate-to-high doses is often initiated in secondary care, but then continued in primary c... Read More about Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study.

Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs (2021)
Journal Article
Collier, F., Howes, R., Rodrigues, J., Thomas, K. S., Leighton, P., & Ingram, J. R. (2021). Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. BJGP Open, 5(5), 1-8. https://doi.org/10.3399/BJGPO.2021.0051

Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that causes painful discharging nodules and skin tunnels. HS has associations with several systemic diseases, including cardiovascular disease (CVD), anxiety, and depress... Read More about Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs.

Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women (2021)
Journal Article
Renz, S., Chinnery, F., Stuart, B., Day, L., Muller, I., Soulsby, I., …Santer, M. (2021). Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women. BMJ Open, 11(8), Article e053876. https://doi.org/10.1136/bmjopen-2021-053876

Introduction Acne is one of the most common inflammatory skin diseases worldwide and can have significant psychosocial impact and cause permanent scarring. Spironolactone, a potassium-sparing diuretic, has antiandrogenic properties, potentially reduc... Read More about Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women.

Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review* (2021)
Journal Article
Howells, L., Lancasterm, N., McPheem, M., Bundy, C., Ingram, J. R., Leighton, P., …Thomas, K. S. (2021). Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review*. British Journal of Dermatology, 185(5), 921-934. https://doi.org/10.1111/bjd.20523

Background: Although hidradenitis suppurativa (HS) is known to affect quality of life, little summative knowledge exists on how HS impacts people living with the condition. Objectives: To synthesize experiences of people with HS within published qual... Read More about Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review*.

Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care Online) interventions for young people and parents/carers (2021)
Journal Article
Muller, I., Stuart, B., Sach, T., Hooper, J., Wilczynska, S., Steele, M., …Santer, M. (2021). Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care Online) interventions for young people and parents/carers. BMJ Open, 11(2), Article e045583. https://doi.org/10.1136/bmjopen-2020-045583

Introduction Eczema care requires management of triggers and various treatments. We developed two online behavioural interventions to support eczema care called ECO (Eczema Care Online) for young people and ECO for families. This protocol describes t... Read More about Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care Online) interventions for young people and parents/carers.

Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting (2021)
Journal Article
Thomas, K., Apfelbacher, C., Chalmers, J., Simpson, E., Spuls, P., Gerbens, L., …Katoh, N. (2021). Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. British Journal of Dermatology, 185(1), 139-146. https://doi.org/10.1111/bjd.19751

Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported si... Read More about Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.